Nirvana Life Sciences Inc. (CSE:NIRV)

Nirvana Life Sciences Income Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 31, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Selling, General & Admin	0.3	0.4	0.79	0.43	0.28
Research & Development	0.03	0.12	0.09	0.32	0.39
Operating Expenses	0.37	0.71	1.18	1.16	0.7
Operating Income	-0.37	-0.71	-1.18	-1.16	-0.7
Interest Expense	-	-0	-0.01	-	-
Interest & Investment Income	-	-	0	0.01	0
Other Non Operating Income (Expenses)	-0.02	-0.03	-0.08	-4.5	-0.03
EBT Excluding Unusual Items	-0.39	-0.74	-1.26	-5.66	-0.73
Asset Writedown	-0.16	-0.16	-0.25	-	-
Other Unusual Items	-	0.03	0.02	-	-
Pretax Income	-0.54	-0.87	-1.49	-5.66	-0.73
Earnings From Continuing Operations	-0.54	-0.87	-1.49	-5.66	-0.73
Minority Interest in Earnings	0	0	0	0	-
Net Income	-0.54	-0.87	-1.49	-5.65	-0.73
Net Income to Common	-0.54	-0.87	-1.49	-5.65	-0.73
Shares Outstanding (Basic)	5	5	3	4	3
Shares Outstanding (Diluted)	5	5	3	4	3
Shares Change (YoY)	4.54%	37.61%	-7.05%	5.19%	-
EPS (Basic)	-0.12	-0.19	-0.44	-1.55	-0.21
EPS (Diluted)	-0.12	-0.19	-0.44	-1.55	-0.21
Free Cash Flow	-0.05	-0.19	-0.33	-0.49	-1.2
Free Cash Flow Per Share	-0.01	-0.04	-0.10	-0.13	-0.35
EBITDA	-0.35	-0.7	-1.08	-1.07	-0.67
D&A For EBITDA	0.02	0.02	0.09	0.09	0.03
EBIT	-0.37	-0.71	-1.18	-1.16	-0.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.